Early Conversion From Tacrolimus to Efalizumab Maintenance Therapy in Kidney Transplant Recipients
Status:
Terminated
Trial end date:
2009-04-01
Target enrollment:
Participant gender:
Summary
The toxicity of calcineurin inhibitors(CNI)is a major factor limiting the success of renal
transplantation. This protocol aims to replace the calcineurin inhibitor, tacrolimus, with
efalizumab early after transplantation in patients with mild impairment of renal function in
order to minimize the toxicities of CNI.